Moreover, PACs exert their therapeutic effects on ulcerative colitis in mice via the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is a key signaling mechanism involved in the regulation of inflammation and immune responses (58). Here, MTOR is linked to ulcerative colitis.